ENGN · enGene Therapeutics Inc. · Executive Compensation
$1.87
-0.07 (-3.61%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Jun 15, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
Market Cap
$125.32M
Shares
67.02M
Volume · Oct 5
952.87K
Avg daily vol (3M)
808.13K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ronald H.W. Cooper | Chief Executive Officer and President | $5,758,289 |
| Hussein Sweiti | Chief Medical Officer | $3,151,902 |
| Ryan Daws | Chief Financial Officer | $2,216,126 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ronald H.W. Cooper | Chief Executive Officer and President | $8,433,812 |
| Lee G. Giguere | Chief Legal Officer & Secretary | $3,303,449 |
| Raj S. Pruthi | MD, MHA, FACS Chief Medical Officer | $2,466,059 |
| Jason D. Hanson | Former Chief Executive Officer | $999,299 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jason D. Hanson | Former Chief Executive Officer | $2,192,934 |
| Alexander Nichols | President and Chief Operating Officer | $969,950 |
| Dr. Alexander Nichols | President and Chief Operating Officer | $969,950 |
| James Sullivan | Chief Scientific Officer | $896,242 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jason D. Hanson | Chief Executive Officer | $649,207 |
| James Sullivan | Chief Scientific Officer | $439,866 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Richard Glickman | director | Resigned | 2026-07-16 |
| Dr. Richard Glickman | chairman of the Board of Directors | Resigned | 2026-07-16 |
| Alex Nichols | Chief Strategy and Operations Officer | Resigned | 2026-06-15 |
| Lee Giguere | Chief Legal Officer and Secretary | Resigned | 2026-06-15 |
| William Grossman | Interim Chief Medical Officer | Appointed | 2026-06-15 |
| Kathleen Richton | Senior Vice President, Finance | Appointed | 2026-06-15 |
| Ryan Daws | Chief Financial Officer | Resigned | 2026-06-15 |
| Hussein Sweiti | Chief Medical Officer and Head of Research and Development | Resigned | 2026-06-15 |
| Michael Heffernan | director | Appointed | 2025-07-08 |
| William Grossman | director | Appointed | 2025-07-08 |
| Philip Astley-Sparke | director | Appointed | 2025-07-08 |
| Jasper Bos | director | Resigned | 2025-07-08 |
| Dr. Raj S. Pruthi | Chief Medical Officer | Resigned | 2025-06-04 |
| Joan Connolly | Chief Technology Officer (CTO) | Appointed | 2024-10-21 |
| Joan Connolly | Chief Technology Officer | Appointed | 2024-10-21 |
| Alexander Nichols | Chief Strategy and Operations Officer | Appointed | 2024-10-21 |
| Anthony Cheung | Chief Scientific Officer | Appointed | 2024-10-21 |
| Ron Cooper | member of the Board of Directors | Appointed | 2024-07-24 |
| Ron Cooper | Chief Executive Officer | Appointed | 2024-07-24 |
| Richard Bryce | Chief Medical Officer | Resigned | 2024-07-24 |
| Raj Pruthi | Chief Medical Officer | Appointed | 2024-07-24 |
| Jason D. Hanson | director | Resigned | 2024-07-24 |
| Jason D. Hanson | Chief Executive Officer | Resigned | 2024-07-24 |
| Ronald H.W. Cooper | director | Appointed | 2024-07-24 |
| Ronald H.W. Cooper | Chief Executive Officer | Appointed | 2024-07-24 |